Viatris Inc. reported second-quarter 2026 financial results, delivering total revenues of $3.8 billion, a 5% increase from the prior year period. The company posted a U.S. GAAP net loss of $119 million and adjusted EPS of $0.69. Adjusted EBITDA rose 8% operationally to $1.2 billion. Viatris raised its full-year 2026 guidance midpoints for total revenues, adjusted EBITDA, adjusted EPS, and free cash flow. The company returned approximately $550 million to shareholders through capital returns, including $270 million in share repurchases, while reducing its gross leverage ratio to 2.9x. Key operational developments include the FDA approval of Gwyn Lo, a new contraceptive patch, and the sale of global rights for Tyrvaya to Harrow, Inc. Manufacturing disruptions at its Nashik, India facility are expected to impact second-half revenues by $100 million to $150 million due to remediation activities following a fire and FDA observations. Viatris is a global healthcare company that develops, manufactures, and markets generic medicines, biosimilars, and innovative branded therapies.

On July 1, 2026, Viatris Inc. entered into an amended and restated term loan credit agreement with Mizuho Bank, Ltd. as administrative agent. The agreement establishes a ¥40,000,000,000 senior unsecured term loan facility to be used for general corporate purposes and to repay an existing ¥40,000,000,000 unsecured term loan facility from 2021. The facility carries an initial interest rate of the TIBO Rate plus 1.10% per annum, with a leverage ratio covenant not to exceed 3.75 to 1.00. The loan is due three years from the closing date. Viatris is a global healthcare company that develops and distributes generic and branded medicines.

Viatris Inc. completed a public offering of €650,000,000 in 4.250% Senior Notes due 2033 on June 17, 2026. The senior unsecured notes are guaranteed by Mylan Inc., Mylan II B.V., and Utah Acquisition Sub Inc. Net proceeds are intended to fund the repayment of the company's $1.675 billion 3.950% Senior Notes due 2026 and to replenish cash for general corporate purposes. The notes carry an annual interest rate of 4.250% and mature on June 17, 2033. Viatris is a global healthcare company that develops and manufactures generic and branded pharmaceutical products.

Viatris Inc. entered into an underwriting agreement on June 12, 2026, to issue and sell €650,000,000 principal amount of 4.250% Senior Notes due 2033. BNP Paribas, Citigroup Global Markets Limited, and Goldman Sachs & Co. LLC are acting as representatives for the underwriters. The offering is expected to close on June 17, 2026. Viatris Inc. is a global healthcare company that develops and manufactures generic and branded pharmaceutical products.